February 10, 2006
Burlington, Ontario
The Jenex Corporation (the "Corporation") has received conditional approval from the TSX Venture Exchange for the previously announced brokered private placement on January 12, 2006, for gross proceeds of $79,252.50.
The private placement raised gross proceeds of $79,252.50 and resulted in the issuance of 528,350 units at a price of 15 cents per unit to investors. Each unit is comprised of one (1) common share of the Corporation and 0.15 of a non-transferable share purchase warrant (79,253 whole warrants in total). Each whole warrant entitles the holder thereof to purchase one (1) additional common share of the Corporation at a price of $0.25 per share for a period of two years commencing on the closing date. In connection with the above, Benson Van Laer & Co. Inc. received a commission of $2,990 in cash and 19,935 warrants, on the same terms as the warrants issued to investors.
All of the securities issued pursuant to the private placement (including conversion shares and shares issued upon exercise of the warrants) are subject to a hold period which expires on June 11, 2006.
In addition to the foregoing, the Corporation is proposing to complete, subject to regulatory approval, a non-brokered private placement of up to 1,000,000 Units at a price of $0.19 per unit to raise up to $190,000. Each unit will consist of one (1) common share of the Corporation and 0.19 of a non-transferable share purchase warrant (190,000 whole warrants in total). Each whole warrant will entitle the holder thereof to purchase one (1) additional common share of the Corporation at a price of $0.30 per common share for a period of two years following the closing date of the private placement. In connection with the foregoing, the Corporation proposes to pay an agent finder fee to Kingsdale Capital Markets Inc., to a maximum of $8000 in cash and 83,000 warrants, on the same terms as the warrants issued to investors.
About The Jenex Corporation
Headquartered in Burlington, Ontario, the Corporation owns a patented Thermal Therapy Technology. Patents in the United States, Canada, Australia, and Europe protect the Technology. The Corporation is currently preparing for the launch of interceptCS™ in the Canadian market in first quarter 2006. interceptCS is the first product proven and approved to prevent cold sores. Jenex has been approved to market interceptCS in Canada with its approved claim, "For prevention and relief of the symptoms of herpes labialis (cold sores), such as blistering, lesions, inflammation, and discomfort. Also helps alleviate the embarrassment that is typically associated with herpes labialis (cold sore) outbreaks".
Enquiries:
Michael A. Jenkins, President
The Jenex Corporation
940 Sheldon Court, Suite 207
Burlington, Ontario
L7L 5K6
Telephone: (905) 632-3830
Facsimile: (905) 632-3774
Email: jenex@jenexcorp.com
The TSX Venture Exchange has not reviewed and does not accept responsibility for the accuracy or the contents of this press release. Certain information included in this press release is forward-looking and is subject to important risks and uncertainties. The results or events predicted in these statements may differ materially from actual results or events.
